Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fresenius Medical Care ( (FMS) ) just unveiled an update.
On June 17, 2025, Fresenius Medical Care AG announced a share buyback program with a total volume of EUR 1 billion, to be executed in tranches over two years starting in the second half of 2025. This strategic move, part of the company’s ‘Strategy FME Reignite,’ aims to enhance shareholder value and reflects the company’s confidence in its financial stability and future growth prospects.
The most recent analyst rating on (FMS) stock is a Hold with a $22.00 price target. To see the full list of analyst forecasts on Fresenius Medical Care stock, see the FMS Stock Forecast page.
Spark’s Take on FMS Stock
According to Spark, TipRanks’ AI Analyst, FMS is a Outperform.
Fresenius Medical Care demonstrates solid financial performance with consistent revenue and strong cash flow. Positive momentum is evident in technical indicators, although valuation metrics suggest potential overvaluation. The company’s strategic initiatives and earnings call guidance support a positive outlook for the year.
To see Spark’s full report on FMS stock, click here.
More about Fresenius Medical Care
Fresenius Medical Care AG is a leading provider in the healthcare industry, specializing in products and services for individuals with chronic kidney failure. The company focuses on dialysis treatments and operates a global network of dialysis clinics.
Average Trading Volume: 454,999
Technical Sentiment Signal: Buy
Current Market Cap: $16.78B
For a thorough assessment of FMS stock, go to TipRanks’ Stock Analysis page.